Intra-Cellular and Takeda terminate the deal granting Takeda worldwide rights to develop and commercialize Intra-Cellular's preclinical phosphodiesterase-1 (PDE-1) inhibitors

Intra-Cellular Therapies Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Takeda Pharmaceutical Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated